ADCT / ADC Therapeutics SA (ADCT) Reports Q4 Loss, Misses Revenue Estimates

ADC Therapeutics SA (ADCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get pre more_horizontal

ADC Therapeutics is a small-cap biotech with an approved antibody-drug conjugate in lymphoma. The company has faced setbacks but has cash on hand and more_horizontal

ADC Therapeutics SA (ADCT) came out with a quarterly loss of $0.58 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to more_horizontal

LAUSANNE, Switzerland, Aug. 01, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that it will host a conference call and live more_horizontal

ADC Therapeutics SA (ADCT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined more_horizontal

ADC Therapeutics (ADCT) pauses patient enrollment in a mid-stage study evaluating Zynlonta in combination with rituximab, for patients with previously more_horizontal

ADC Therapeutics said on Tuesday it had paused enrollment of new patients in a mid-stage study evaluating its drug Zynlonta along with rituximab for t more_horizontal

ADC Therapeutics SA (ADCT) came out with a quarterly loss of $0.74 per share versus the Zacks Consensus Estimate of a loss of $0.80. This compares to more_horizontal